Novo Nordisk reports Q1 adjusted EPS DKK 6.63 vs. DKK 6.82 last year

Reports Q1 revenue DKK 96.82B vs. DKK 78.09B last year. The company said, “Wegovy is driving a strong start to 2026 for Novo Nordisk (NVO), led by the rapid adoption of Wegovy pill – the most efficacious GLP-1 tablet now used by more than one million patients since its January launch. As the global momentum behind peptide based therapies accelerates, Wegovy pill is defining a novel category as the only oral peptide for the treatment of obesity, setting a new benchmark for what patients and physicians can expect. The strong Wegovy performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit,” said Mike Doustdar, president and CEO of Novo Nordisk. “During the quarter, we also secured multiple approvals for Wegovy HD, strengthening the Wegovy portfolio, and enabling patients to achieve nearly 21% weight loss.”